EMA Expedites Cancer Drug
European Medicines Agency Fast-Tracks Revolution Medicines' Daraxonrasib for Pancreatic Cancer Assessment
Anonymous
The European Medicines Agency (EMA) has launched a phased review of daraxonrasib, an investigational drug from Revolution Medicines targeting pancreatic cancer, according to Calgary Sun. The move is designed to speed up the assessment process by evaluating clinical data as it becomes available, rather than waiting for a complete submission.
The push comes as Revolution Medicines advances its pivotal Phase 3 trial called RASolute 302. The EMA's Committee for Medicinal Products for Human Use, known as the CHMP, has also granted daraxonrasib orphan medicinal product status for pancreatic cancer — a designation reserved for treatments targeting rare or serious diseases, Market Screener reported.
What a Phased Review Means for Patients
A phased review, also called a rolling review, lets regulators examine data in batches as trial results come in. This is faster than the standard process, where companies must submit all data at once before any review begins. The EMA has used this tool before to speed up access to promising treatments, including during the COVID-19 pandemic.
For pancreatic cancer patients, speed matters enormously. Pancreatic cancer is one of the deadliest cancers, with very few treatment options that meaningfully extend survival. Getting a new drug reviewed faster could translate directly into earlier patient access if the drug is approved, according to Daily Herald Tribune.
Daraxonrasib Targets the Hard-to-Hit RAS Gene
Daraxonrasib is designed to block RAS proteins — genetic drivers found in a large share of pancreatic cancers. RAS mutations have long been considered nearly impossible to target with drugs, making Revolution Medicines' approach a significant scientific bet, Paris Star reported.
The drug is now being evaluated in the Phase 3 RASolute 302 trial. Results from this study form the core of the data package being submitted to both European and U.S. regulators. Revolution Medicines has not yet disclosed specific efficacy numbers from the trial publicly, according to Mitchell Advocate.
U.S. FDA Review Also Moving Forward in Parallel
On the U.S. side, Revolution Medicines is making progress on a rolling New Drug Application, or NDA, submitted to the FDA, according to Fort Saskatchewan Record. The company is filing data in stages under the FDA's rolling submission process, which mirrors the EMA's phased approach.
The FDA submission is also operating under the Commissioner's National Priority Voucher pilot program — a newer initiative meant to fast-track drugs for high-priority unmet medical needs. Together, the dual-track regulatory strategy in both the U.S. and Europe signals that Revolution Medicines is pushing hard for the fastest possible path to approval, Calgary Sun noted.
Orphan Drug Status Adds Another Layer of Support
The CHMP's orphan medicinal product designation gives daraxonrasib extra regulatory benefits in Europe. These include longer market exclusivity — up to 10 years — and reduced regulatory fees. The designation reflects the serious, life-threatening nature of pancreatic cancer and the lack of adequate existing treatments, according to Market Screener.
Pancreatic cancer affects a relatively small patient population each year compared to more common cancers, which qualifies it for orphan status under EMA rules. For Revolution Medicines, the designation adds commercial protection on top of the scientific momentum the company is building across two major regulatory markets, Sault Star reported.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
7
Articles
7
Reach
7
A
AnonymousAuthor
